Search for content, post, videos

Oncopeptides provides update on US marketing authorization

Jakob Lindberg
Oncopeptides has announced that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto. The request is based on the outcome of the confirmatory phase 3 OCEAN study, which demonstrated an ITT overall survival HR of 1.1, but with significa
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.